In Vivo: Mocravimod hydrochloride (KRP-203) ameliorates atherosclerosis in LDL-R / Mice. Mocravimod hydrochloride (KRP-203) (orally; 0.1 and 1 mg/kg/day; for 100 days) prolongs graft survival and attenuates chronic rejection in mHC-disparate rat heart allografts.